The management of visceral pain in patients with disorders of gut–brain interaction, notably irritable bowel syndrome, presents a considerable clinical challenge, with few available treatment options. Patients are increasingly using cannabis and cannabinoids to control abdominal pain. Cannabis acts on receptors of the endocannabinoid system, an endogenous system of lipid mediators that regulates gastrointestinal function and pain processing pathways in health and disease. The endocannabinoid system represents a logical molecular therapeutic target for the treatment of pain in irritable bowel syndrome. Here, we review the physiological and pathophysiological functions of the endocannabinoid system with a focus on the peripheral and central regulation of gastrointestinal function and visceral nociception. We address the use of cannabinoids in pain management, comparing them to other treatment modalities, including opioids and neuromodulators. Finally, we discuss emerging therapeutic candidates targeting the endocannabinoid system for the treatment of pain in irritable bowel syndrome.
The management of abdominal pain in disorders of gut–brain interaction, including irritable bowel syndrome (IBS), is challenging.
Patients are increasingly using cannabis and cannabinoids as an alternative therapy to treat pain and altered bowel habits in IBS.
Cannabis acts on the cannabinoid receptors (CB1 and CB2) of the endocannabinoid system (ECS), which consists of ligands for these receptors, anandamide and 2-arachidonoylglycerol as well as the biosynthetic and degradative enzymes for these ligands.
The ECS is a logical molecular target for the treatment of IBS as it regulates gastrointestinal motility, secretion, barrier function, inflammation, gut microbiota and visceral sensitivity.
Cannabinoid therapeutics have been developed but are of limited use in managing pain in IBS; the effects of cannabis have not been rigorously examined in much-needed large clinical trials.
Evidence supports the putative analgesic properties of a peripherally restricted CB2 receptor agonist in IBS. Future therapies could target additional ECS components for the treatment of IBS and other disorders of gut–brain interaction.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Drossman, D. A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 150, 1262–1279 (2016).
Sperber, A. D. et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology 160, 99–114 (2021).
Mearin, F. et al. Bowel disorders. Gastroenterology 150, 1393–1407 (2016).
Vanuytsel, T., Tack, J. F. & Boeckxstaens, G. E. Treatment of abdominal pain in irritable bowel syndrome. J. Gastroenterol. 49, 1193–1205 (2014).
Simren, M. et al. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut 67, 255–262 (2018).
Drossman, D. A. et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation Working Team Report. Gastroenterology 154, 1140–1171 (2018).
Cohen, L. & Neuman, M. G. Cannabis and the gastrointestinal tract. J. Pharm. Pharm. Sci. 23, 301–313 (2020).
Gotfried, J., Naftali, T. & Schey, R. Role of cannabis and its derivatives in gastrointestinal and hepatic disease. Gastroenterology 159, 62–80 (2020).
Nasser, Y., Woo, M. & Andrews, C. N. Cannabis in gastroenterology: watch your head! A review of use in inflammatory bowel disease, functional gut disorders, and gut-related adverse effects. Curr. Treat. Options Gastroenterol. 18, 519–530 (2020).
DiPatrizio, N. V. Endocannabinoids in the gut. Cannabis Cannabinoid Res. 1, 67–77 (2016).
Maselli, D. B. & Camilleri, M. Pharmacology, clinical effects, and therapeutic potential of cannabinoids for gastrointestinal and liver diseases. Clin. Gastroenterol. Hepatol. 19, 1748–1758 (2021).
Sharkey, K. A. & Wiley, J. W. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology 151, 252–266 (2016).
Pesce, M., Esposito, G. & Sarnelli, G. Endocannabinoids in the treatment of gasytrointestinal inflammation and symptoms. Curr. Opin. Pharmacol. 43, 81–86 (2018).
Storr, M. A., Yuce, B., Andrews, C. N. & Sharkey, K. A. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol. Motil. 20, 857–868 (2008).
Mechoulam, R., Hanus, L. O., Pertwee, R. & Howlett, A. C. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 15, 757–764 (2014).
Di Marzo, V. New approaches and challenges to targeting the endocannabinoid system. Nat. Rev. Drug Discov. 17, 623–639 (2018).
Fowler, C. J., Doherty, P. & Alexander, S. P. H. Endocannabinoid turnover. Adv. Pharmacol. 80, 31–66 (2017).
Blankman, J. L. & Cravatt, B. F. Chemical probes of endocannabinoid metabolism. Pharmacol. Rev. 65, 849–871 (2013).
van Egmond, N., Straub, V. M. & van der Stelt, M. Targeting endocannabinoid signaling: FAAH and MAG lipase inhibitors. Annu. Rev. Pharmacol. Toxicol. 61, 441–463 (2021).
Hill, M. N. & Patel, S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol. Mood Anxiety Disord. 3, 19 (2013).
Lutz, B., Marsicano, G., Maldonado, R. & Hillard, C. J. The endocannabinoid system in guarding against fear, anxiety and stress. Nat. Rev. Neurosci. 16, 705–718 (2015).
Kaczocha, M., Glaser, S. T. & Deutsch, D. G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl Acad. Sci. USA 106, 6375–6380 (2009).
Haj-Dahmane, S. et al. Fatty-acid-binding protein 5 controls retrograde endocannabinoid signaling at central glutamate synapses. Proc. Natl Acad. Sci. USA 115, 3482–3487 (2018).
Cristino, L., Bisogno, T. & Di Marzo, V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 16, 9–29 (2020).
Abyadeh, M. et al. A proteomic view of cellular and molecular effects of cannabis. Biomolecules 11, 1411 (2021).
Hua, T. et al. Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures. Cell 180, 655–665 (2020).
Krishna Kumar, K. et al. Structure of a signaling cannabinoid receptor 1-G protein complex. Cell 176, 448–458 (2019).
Li, X. et al. Crystal structure of the human cannabinoid receptor CB2. Cell 176, 459–467 (2019).
Moreira, F. A., Grieb, M. & Lutz, B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 23, 133–144 (2009).
Jimenez-Blasco, D. et al. Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature 583, 603–608 (2020).
Soria-Gomez, E. et al. Subcellular specificity of cannabinoid effects in striatonigral circuits. Neuron 109, 1513–1526 (2021).
Duncan, M. et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G78–G87 (2008).
Merriam, F. V., Wang, Z. Y., Guerios, S. D. & Bjorling, D. E. Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci. Lett. 445, 130–134 (2008).
Wright, K. et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129, 437–453 (2005).
Han, S., Thatte, J., Buzard, D. J. & Jones, R. M. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J. Med. Chem. 56, 8224–8256 (2013).
Castro, J. et al. Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents. Pain 163, e72–e86 (2022).
Jordan, C. J. & Xi, Z. X. Progress in brain cannabinoid CB2 receptor research: from genes to behavior. Neurosci. Biobehav. Rev. 98, 208–220 (2019).
Howlett, A. C. & Abood, M. E. CB1 and CB2 receptor pharmacology. Adv. Pharmacol. 80, 169–206 (2017).
Lutz, B. Neurobiology of cannabinoid receptor signaling. Dialogues Clin. Neurosci. 22, 207–222 (2020).
Booth, W. T., Walker, N. B., Lowther, W. T. & Howlett, A. C. Cannabinoid receptor interacting protein 1a (CRIP1a): function and structure. Molecules 24, 3672 (2019).
Camilleri, M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol. Motil. 30, e13370 (2018).
Izzo, A. A. & Sharkey, K. A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Ther. 126, 21–38 (2010).
Hons, I. M. et al. Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol. Motil. 24, e113–e124 (2012).
Boesmans, W., Ameloot, K., van den Abbeel, V., Tack, J. & Vanden Berghe, P. Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol. Motil. 21, 958–e77 (2009).
Fichna, J., Sibaev, A., Salaga, M., Sobczak, M. & Storr, M. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterol. Motil. 25, e550–e559 (2013).
Storr, M. A. et al. Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol. Motil. 22, 787–796 (2010).
Drokhlyansky, E. et al. The human and mouse enteric nervous system at single-cell resolution. Cell 182, 1606–1622 (2020).
Jiang, Y., Nie, Y., Li, Y. & Zhang, L. Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome. J. Gastroenterol. Hepatol. 29, 1186–1191 (2014).
Wong, B. S. et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 141, 1638–1647 (2011).
Bashashati, M. et al. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br. J. Pharmacol. 165, 1556–1571 (2012).
Kimball, E. S., Wallace, N. H., Schneider, C. R., D’Andrea, M. R. & Hornby, P. J. Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice. Front. Pharmacol. 1, 132 (2010).
Lin, M., Chen, L., Xiao, Y. & Yu, B. Activation of cannabinoid 2 receptor relieves colonic hypermotility in a rat model of irritable bowel syndrome. Neurogastroenterol. Motil. 31, e13555 (2019).
Bashashati, M. et al. Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. Br. J. Pharmacol. 172, 3099–3111 (2015).
Crowe, M. S. & Kinsey, S. G. MAGL inhibition modulates gastric secretion and motility following NSAID exposure in mice. Eur. J. Pharmacol. 807, 198–204 (2017).
Fichna, J. et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol. Motil. 26, 470–481 (2014).
Taschler, U. et al. Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic mu-opioid receptor sensitivity. Br. J. Pharmacol. 172, 4419–4429 (2015).
Capasso, R. et al. Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB(1) receptors and TRPV1 channels. Br. J. Pharmacol. 171, 4026–4037 (2014).
Zhang, S. C., Wang, W. L., Su, P. J., Jiang, K. L. & Yuan, Z. W. Decreased enteric fatty acid amide hydrolase activity is associated with colonic inertia in slow transit constipation. J. Gastroenterol. Hepatol. 29, 276–283 (2014).
Camilleri, M. et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G13–G19 (2008).
Ameloot, K. et al. Endocannabinoid control of gastric sensorimotor function in man. Aliment. Pharmacol. Ther. 31, 1123–1131 (2010).
Scarpellini, E. et al. Effect of rimonabant on oesophageal motor function in man. Aliment. Pharmacol. Ther. 33, 730–737 (2011).
Tack, J. et al. The gastrointestinal tract in hunger and satiety signalling. UEG J. 9, 727–734 (2021).
Tyler, K., Hillard, C. J. & Greenwood-Van Meerveld, B. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur. J. Pharmacol. 409, 207–211 (2000).
MacNaughton, W. K. et al. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G863–G871 (2004).
Izzo, A. A. et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125, 765–774 (2003).
Alhamoruni, A., Lee, A. C., Wright, K. L., Larvin, M. & O’Sullivan, S. E. Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J. Pharmacol. Exp. Ther. 335, 92–102 (2010).
Alhamoruni, A., Wright, K. L., Larvin, M. & O’Sullivan, S. E. Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br. J. Pharmacol. 165, 2598–2610 (2012).
Karwad, M. A. et al. The role of CB1 in intestinal permeability and inflammation. FASEB J. 31, 3267–3277 (2017).
Muccioli, G. G. et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol. Syst. Biol. 6, 392 (2010).
Dothel, G. et al. micro-opioid receptor, beta-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol. Motil. 31, e13688 (2019).
Cabral, G. A., Ferreira, G. A. & Jamerson, M. J. Endocannabinoids and the immune system in health and disease. Handb. Exp. Pharmacol. 231, 185–211 (2015).
Duffy, S. S., Hayes, J. P., Fiore, N. T. & Moalem-Taylor, G. The cannabinoid system and microglia in health and disease. Neuropharmacology 190, 108555 (2021).
Turcotte, C., Blanchet, M. R., Laviolette, M. & Flamand, N. The CB2 receptor and its role as a regulator of inflammation. Cell Mol. Life Sci. 73, 4449–4470 (2016).
Brierley, S. M. & Linden, D. R. Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat. Rev. Gastroenterol. Hepatol. 11, 611–627 (2014).
Storr, M. A. et al. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm. Bowel Dis. 15, 1678–1685 (2009).
Leinwand, K. L. et al. Cannabinoid receptor-2 ameliorates inflammation in murine model of Crohn’s disease. J. Crohns Colitis 11, 1369–1380 (2017).
Cremon, C. et al. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment. Pharmacol. Ther. 45, 909–922 (2017).
Alhouayek, M., Ameraoui, H. & Muccioli, G. G. Bioactive lipids in inflammatory bowel diseases - from pathophysiological alterations to therapeutic opportunities. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1866, 158854 (2021).
Picardo, S., Kaplan, G. G., Sharkey, K. A. & Seow, C. H. Insights into the role of cannabis in the management of inflammatory bowel disease. Ther. Adv. Gastroenterol. 12, 1756284819870977 (2019).
Fichna, J. et al. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. PLoS ONE 9, e109115 (2014).
Szabady, R. L. et al. Intestinal P-glycoprotein exports endocannabinoids to prevent inflammation and maintain homeostasis. J. Clin. Invest. 128, 4044–4056 (2018).
Foley, S. E. et al. Gut microbiota regulation of P-glycoprotein in the intestinal epithelium in maintenance of homeostasis. Microbiome 9, 183 (2021).
Brusberg, M. et al. CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents. J. Neurosci. 29, 1554–1564 (2009).
Hong, S. et al. Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut 58, 202–210 (2009).
Iwata, Y. et al. Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg. Med. Chem. Lett. 25, 236–240 (2015).
Kikuchi, A., Ohashi, K., Sugie, Y., Sugimoto, H. & Omura, H. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J. Pharmacol. Sci. 106, 219–224 (2008).
Sanson, M., Bueno, L. & Fioramonti, J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol. Motil. 18, 949–956 (2006).
Naguib, M. et al. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br. J. Pharmacol. 155, 1104–1116 (2008).
Enck, P. et al. Irritable bowel syndrome. Nat. Rev. Dis. Prim. 2, 16014 (2016).
Shen, L., Yang, X. J., Qian, W. & Hou, X. H. The role of peripheral cannabinoid receptors type 1 in rats with visceral hypersensitivity induced by chronic restraint stress. J. Neurogastroenterol. Motil. 16, 281–290 (2010).
Hillsley, K. et al. Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol. Motil. 19, 769–777 (2007).
Sadeghi, M. et al. Contribution of membrane receptor signalling to chronic visceral pain. Int. J. Biochem. Cell Biol. 98, 10–23 (2018).
Prato, V. et al. Functional and molecular characterization of mechanoinsensitive “Silent” nociceptors. Cell Rep. 21, 3102–3115 (2017).
Schaefer, I., Prato, V., Arcourt, A., Taberner, F. J. & Lechner, S. G. Differential modulation of voltage-gated sodium channels by nerve growth factor in three major subsets of TrkA-expressing nociceptors. Mol. Pain 14, 1744806918814640 (2018).
Dothel, G. et al. Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 148, 1002–1011 (2015).
Sarnelli, G. et al. Impaired duodenal palmitoylethanolamide release underlies acid-induced mast cell activation in functional dyspepsia. Cell Mol. Gastroenterol. Hepatol. 11, 841–855 (2021).
Barbara, G. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126, 693–702 (2004).
Barbara, G. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132, 26–37 (2007).
Aguilera-Lizarraga, J. et al. Local immune response to food antigens drives meal-induced abdominal pain. Nature 590, 151–156 (2021).
Farquhar-Smith, W. P., Jaggar, S. I. & Rice, A. S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors. Pain 97, 11–21 (2002).
Cantarella, G. et al. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem. Pharmacol. 82, 380–388 (2011).
Costa, B., Comelli, F., Bettoni, I., Colleoni, M. & Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139, 541–550 (2008).
Petrosino, S. et al. Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. J. Neuroinflammation 16, 274 (2019).
Domoto, R., Sekiguchi, F., Tsubota, M. & Kawabata, A. Macrophage as a peripheral pain regulator. Cells 10, 1881 (2021).
Cattaruzza, F. et al. Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. Gastroenterology 141, 1864–1874 (2011).
Jimenez-Vargas, N. N. et al. Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. Proc. Natl Acad. Sci. USA 115, E7438–E7447 (2018).
Grubišić, V. et al. Enteric glia modulate macrophage phenotype and visceral sensitivity following inflammation. Cell Rep. 32, 108100 (2020).
Esposito, G. et al. Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-alpha activation. Gut 63, 1300–1312 (2014).
Acharya, N. et al. Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proc. Natl Acad. Sci. USA 114, 5005–5010 (2017).
Basso, L. et al. Granulocyte-colony-stimulating factor (G-CSF) signaling in spinal microglia drives visceral sensitization following colitis. Proc. Natl Acad. Sci. USA 114, 11235–11240 (2017).
Yuan, T., Manohar, K., Latorre, R., Orock, A. & Greenwood-Van Meerveld, B. Inhibition of microglial activation in the amygdala reverses stress-induced abdominal pain in the male rat. Cell Mol. Gastroenterol. Hepatol. 10, 527–543 (2020).
Yuan, T., Orock, A. & Greenwood-Van Meerveld, B. Amygdala microglia modify neuronal plasticity via complement C1q/C3-CR3 signaling and contribute to visceral pain in a rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 320, G1081–G1092 (2021).
Zhang, G. et al. Activation of corticotropin-releasing factor neurons and microglia in paraventricular nucleus precipitates visceral hypersensitivity induced by colorectal distension in rats. Brain Behav. Immun. 55, 93–104 (2016).
Zhang, G. et al. Hippocampal microglial activation and glucocorticoid receptor down-regulation precipitate visceral hypersensitivity induced by colorectal distension in rats. Neuropharmacology 102, 295–303 (2016).
Mayer, E. A., Labus, J. S., Tillisch, K., Cole, S. W. & Baldi, P. Towards a systems view of IBS. Nat. Rev. Gastroenterol. Hepatol. 12, 592–605 (2015).
Martín-Pérez, C. et al. Endocannabinoid signaling of homeostatic status modulates functional connectivity in reward and salience networks. Psychopharmacology 239, 1311–1319 (2021).
Sisk, L. M. et al. Genetic variation in endocannabinoid signaling is associated with differential network-level functional connectivity in youth. J. Neurosci. Res. 100, 731–743 (2022).
Yasmin, F. et al. Stress-induced modulation of endocannabinoid signaling leads to delayed strengthening of synaptic connectivity in the amygdala. Proc. Natl Acad. Sci. USA 117, 650–655 (2020).
Benedetti, F., Amanzio, M., Rosato, R. & Blanchard, C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat. Med. 17, 1228–1230 (2011).
Peciña, M. et al. FAAH selectively influences placebo effects. Mol. Psychiatry 19, 385–391 (2014).
Enck, P. & Klosterhalfen, S. Placebo responses and Placebo effects in functional gastrointestinal disorders. Front. Psychiatry 11, 797 (2020).
Meerveld, B. G. & Johnson, A. C. Mechanisms of stress-induced visceral pain. J. Neurogastroenterol. Motil. 24, 7–18 (2018).
Mahurkar-Joshi, S. & Chang, L. Epigenetic mechanisms in irritable bowel syndrome. Front. Psychiatry 11, 805 (2020).
McEwen, B. S. et al. Mechanisms of stress in the brain. Nat. Neurosci. 18, 1353–1363 (2015).
Rusconi, F., Rubino, T. & Battaglioli, E. Endocannabinoid-epigenetic cross-talk: a bridge toward stress coping. Int. J. Mol. Sci. 21, 6252 (2020).
Tran, L., Chaloner, A., Sawalha, A. H. & Greenwood Van-Meerveld, B. Importance of epigenetic mechanisms in visceral pain induced by chronic water avoidance stress. Psychoneuroendocrinology 38, 898–906 (2013).
Hong, S., Zheng, G. & Wiley, J. W. Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system. Gastroenterology 148, 148–157 (2015).
Osadchiy, V., Martin, C. R. & Mayer, E. A. The gut-brain axis and the microbiome: mechanisms and clinical implications. Clin. Gastroenterol. Hepatol. 17, 322–332 (2019).
Pittayanon, R. et al. Gut microbiota in patients with irritable bowel syndrome-a systematic review. Gastroenterology 157, 97–108 (2019).
Simren, M. et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62, 159–176 (2013).
Esquerre, N. et al. Colitis-induced microbial perturbation promotes postinflammatory visceral hypersensitivity. Cell Mol. Gastroenterol. Hepatol. 10, 225–244 (2020).
Reigstad, C. S. et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 29, 1395–1403 (2015).
Sugisawa, E. et al. RNA sensing by gut Piezo1 is essential for systemic serotonin synthesis. Cell 182, 609–624 (2020).
Anitha, M., Vijay-Kumar, M., Sitaraman, S. V., Gewirtz, A. T. & Srinivasan, S. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 143, 1006–1016 (2012).
Brun, P. et al. Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology 145, 1323–1333 (2013).
Yarandi, S. S. et al. Intestinal bacteria maintain adult enteric nervous system and nitrergic neurons via Toll-like receptor 2-induced neurogenesis in mice. Gastroenterology 159, 200–213 (2020).
Obata, Y. et al. Neuronal programming by microbiota regulates intestinal physiology. Nature 578, 284–289 (2020).
Lyte, M. Microbial endocrinology: an ongoing personal journey. Adv. Exp. Med. Biol. 874, 1–24 (2016).
Sharkey, K. A. & Savidge, T. C. Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract. Auton. Neurosci. 181, 94–106 (2014).
DiPatrizio, N. V. & Piomelli, D. Intestinal lipid-derived signals that sense dietary fat. J. Clin. Invest. 125, 891–898 (2015).
Everard, A. et al. Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis. Nat. Commun. 10, 457 (2019).
Castonguay-Paradis, S. et al. Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat. Sci. Rep. 10, 15975 (2020).
Christie, S., O’Rielly, R., Li, H., Wittert, G. A. & Page, A. J. Biphasic effects of methanandamide on murine gastric vagal afferent mechanosensitivity. J. Physiol. 598, 139–150 (2020).
Lacroix, S. et al. Rapid and concomitant gut microbiota and endocannabinoidome response to diet-induced obesity in mice. mSystems 4, e00407-19 (2019).
DiPatrizio, N. V. et al. Fasting stimulates 2-AG biosynthesis in the small intestine: role of cholinergic pathways. Am. J. Physiol. Regul. Integr. Comp. Physiol. 309, R805–R813 (2015).
Hong, S. et al. Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology 140, 627–637 (2011).
Keenan, C. M. et al. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br. J. Pharmacol. 172, 2406–2418 (2015).
Salaga, M. et al. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. Eur. J. Pharmacol. 836, 34–43 (2018).
Sticht, M. A. et al. Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats. Br. J. Pharmacol. 176, 1524–1540 (2019).
Cryan, J. F. et al. The microbiota-gut-brain axis. Physiol. Rev. 99, 1877–2013 (2019).
Manca, C. et al. Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling. J. Lipid Res. 61, 70–85 (2020).
Manca, C. et al. Alterations of brain endocannabinoidome signaling in germ-free mice. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1865, 158786 (2020).
Kennedy, E. A., King, K. Y. & Baldridge, M. T. Mouse microbiota models: comparing germ-free mice and antibiotics treatment as tools for modifying gut bacteria. Front. Physiol. 9, 1534 (2018).
Aguilera, M., Cerda-Cuellar, M. & Martinez, V. Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. Gut Microbes 6, 10–23 (2015).
Aguilera, M., Vergara, P. & Martinez, V. Stress and antibiotics alter luminal and wall-adhered microbiota and enhance the local expression of visceral sensory-related systems in mice. Neurogastroenterol. Motil. 25, e515–e529 (2013).
Guida, F. et al. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain Behav. Immun. 67, 230–245 (2018).
Rousseaux, C. et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 13, 35–37 (2007).
Markey, L. et al. Colonization with the commensal fungus Candida albicans perturbs the gut-brain axis through dysregulation of endocannabinoid signaling. Psychoneuroendocrinology 121, 104808 (2020).
Chevalier, G. et al. Effect of gut microbiota on depressive-like behaviors in mice is mediated by the endocannabinoid system. Nat. Commun. 11, 6363 (2020).
Minichino, A. et al. Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort. Mol. Psychiatry 26, 6269–6276 (2021).
Cluny, N. L., Keenan, C. M., Reimer, R. A., Le Foll, B. & Sharkey, K. A. Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with Delta9-tetrahydrocannabinol. PLoS ONE 10, e0144270 (2015).
Mehrpouya-Bahrami, P. et al. Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Sci. Rep. 7, 15645 (2017).
Oza, M. et al. Acute and short-term administrations of Δ-9-tetrahydrocannabinol modulate major gut metabolomic regulatory pathways in C57BL/6 mice. Sci. Rep. 9, 10520 (2019).
Al-Ghezi, Z. Z., Busbee, P. B., Alghetaa, H., Nagarkatti, P. S. & Nagarkatti, M. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Brain Behav. Immun. 82, 25–35 (2019).
Ellermann, M. et al. Endocannabinoids inhibit the induction of virulence in enteric pathogens. Cell 183, 650–665 (2020).
Dione, N. et al. Mgll knockout mouse resistance to diet-induced dysmetabolism is associated with altered gut microbiota. Cells 9, 2705 (2020).
Cani, P. D. et al. Endocannabinoids — at the crossroads between the gut microbiota and host metabolism. Nat. Rev. Endocrinol. 12, 133–143 (2016).
Spiller, R. Impact of diet on symptoms of the irritable bowel syndrome. Nutrients 13, 575 (2021).
Uranga, J. A., Martínez, V. & Abalo, R. Mast cell regulation and irritable bowel syndrome: effects of food components with potential nutraceutical use. Molecules 25, 4314 (2020).
Di Marzo, V. & Silvestri, C. Lifestyle and metabolic syndrome: contribution of the endocannabinoidome. Nutrients 11, 1956 (2019).
Kleberg, K., Hassing, H. A. & Hansen, H. S. Classical endocannabinoid-like compounds and their regulation by nutrients. Biofactors 40, 363–372 (2014).
Hansen, H. S. Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat. Pharmacol. Res. 86, 18–25 (2014).
Matias, I. et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol. Cell Endocrinol. 286, S66–S78 (2008).
Diep, T. A. et al. Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor. FASEB J. 25, 765–774 (2011).
Komarnytsky, S. et al. Endocannabinoid system and its regulation by polyunsaturated fatty acids and full spectrum hemp oils. Int. J. Mol. Sci. 22, 5479 (2021).
Larrieu, T. & Layé, S. Food for mood: relevance of nutritional omega-3 fatty acids for depression and anxiety. Front. Physiol. 9, 1047 (2018).
Gigante, I. et al. Cannabinoid receptors overexpression in a rat model of irritable bowel syndrome (IBS) after treatment with a Ketogenic diet. Int. J. Mol. Sci. 22, 2880 (2021).
Martínez, V. et al. Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: useful nutraceuticals? Int. J. Mol. Sci. 21, 3067 (2020).
van Orten-Luiten, A. B., de Roos, N. M., Majait, S., Witteman, B. J. M. & Witkamp, R. F. Effects of cannabidiol chewing gum on perceived pain and well-being of irritable bowel syndrome patients: a placebo-controlled crossover exploratory intervention study with symptom-driven dosing. Cannabis Cannabinoid Res. 7, 436–444 (2021).
Van den Houte, K. et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. UEG J. 7, 307–315 (2019).
Black, C. J. & Ford, A. C. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 17, 473–486 (2020).
Posserud, I. et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 133, 1113–1123 (2007).
Tornblom, H. et al. Colonic transit time and IBS symptoms: what’s the link? Am. J. Gastroenterol. 107, 754–760 (2012).
Simren, M. et al. Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology 157, 391–402 (2019).
Azpiroz, F. Hypersensitivity in functional gastrointestinal disorders. Gut 51, i25–i28 (2002).
Azpiroz, F. et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol. Motil. 19, 62–88 (2007).
Barbara, G. et al. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr. Gastroenterol. Rep. 13, 308–315 (2011).
Malcolm, A., Phillips, S. F., Kellow, J. E. & Cousins, M. J. Direct clinical evidence for spinal hyperalgesia in a patient with irritable bowel syndrome. Am. J. Gastroenterol. 96, 2427–2431 (2001).
Mertz, H. Review article: visceral hypersensitivity. Aliment. Pharmacol. Ther. 17, 623–633 (2003).
Bhattarai, Y., Muniz Pedrogo, D. A. & Kashyap, P. C. Irritable bowel syndrome: a gut microbiota-related disorder? Am. J. Physiol. Gastrointest. Liver Physiol. 312, G52–G62 (2017).
Akbar, A. et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 57, 923–929 (2008).
Shiha, M. G., Ashgar, Z., Fraser, E. M., Kurien, M. & Aziz, I. High prevalence of primary bile acid diarrhoea in patients with functional diarrhoea and irritable bowel syndrome-diarrhoea, based on Rome III and Rome IV criteria. EClinicalMedicine 25, 100465 (2020).
Halvorson, H. A., Schlett, C. D. & Riddle, M. S. Postinfectious irritable bowel syndrome–a meta-analysis. Am. J. Gastroenterol. 101, 1894–1899 (2006).
Jalanka-Tuovinen, J. et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63, 1737–1745 (2014).
Paula, H. et al. Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders. Neurogastroenterol. Motil. 27, 1580–1586 (2015).
Heitkemper, M., Jarrett, M., Bond, E. F. & Chang, L. Impact of sex and gender on irritable bowel syndrome. Biol. Res. Nurs. 5, 56–65 (2003).
Naliboff, B. D. et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology 124, 1738–1747 (2003).
Hubbard, C. S. et al. Estrogen-dependent visceral hypersensitivity following stress in rats: an fMRI study. Mol. Pain 12, 1744806916654145 (2016).
Jiang, Y., Greenwood-Van Meerveld, B., Johnson, A. C. & Travagli, R. A. Role of estrogen and stress on the brain-gut axis. Am. J. Physiol. Gastrointest. Liver Physiol. 317, G203–G209 (2019).
Mulak, A., Taché, Y. & Larauche, M. Sex hormones in the modulation of irritable bowel syndrome. World J. Gastroenterol. 20, 2433–2448 (2014).
Bradford, K. et al. Association between early adverse life events and irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 10, 385–390 (2012).
Chaloner, A. & Greenwood-Van Meerveld, B. Sexually dimorphic effects of unpredictable early life adversity on visceral pain behavior in a rodent model. J. Pain 14, 270–280 (2013).
Rastelli, D. et al. Diminished androgen levels are linked to irritable bowel syndrome and cause bowel dysfunction in mice. J. Clin. Invest. 132, e150789 (2022).
Blanton, H. L. et al. Sex differences and the endocannabinoid system in pain. Pharmacol. Biochem. Behav. 202, 173107 (2021).
Simren, M. & Tack, J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat. Rev. Gastroenterol. Hepatol. 15, 589–605 (2018).
Dapoigny, M., Abitbol, J. L. & Fraitag, B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig. Dis. Sci. 40, 2244–2249 (1995).
Delvaux, M. et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 116, 38–45 (1999).
Mangel, A. W. et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 28, 239–249 (2008).
Szarka, L. A. et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 5, 1268–1275 (2007).
Delvaux, M. et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 20, 237–246 (2004).
Dukes, G. et al. Lack of effect of the NH3 receptor antagonist, talnetant SB223412, on symptoms of IBS: results of 2 randomized, double-blind, placebo-controlled dose-ranging trials. Gastroenterology 132, A60 (2007).
Houghton, L. A. et al. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol. Motil. 19, 732–743 (2007).
Delvaux, M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 51, i67–i71 (2002).
Lecci, A., Altamura, M., Capriati, A. & Maggi, C. A. Tachykinin receptors and gastrointestinal motility: focus on humans. Eur. Rev. Med. Pharmacol. Sci. 12, 69–80 (2008).
Tack, J. et al. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut 66, 1403–1413 (2017).
Lee, O., Munakata, J., Naliboff, B., Chang, L. & Mayer, E. A double-blind parallel group pilot study of the effect of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBSs patients. Gastroenterology. 118, https://doi.org/10.1016/S0016-5085(00)85527-4 (2000).
Tillisch, K. et al. Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment. Pharmacol. Ther. 35, 360–367 (2012).
Akyuz, F., Mimidis, K., Nikolai, H., Vos, R. & Tack, J. Influence of NK1 receptor antagonist aprepitant on rectal sensitivity and compliance in healthy volunteers. Gastroenterology 32, A684 (2007).
Zakko, S., Barton, G., Weber, E., Dunger-Baldauf, C. & Ruhl, A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 33, 1311–1321 (2011).
Kelleher, D. et al. Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol. Motil. 20, 131–132 (2008).
Drossman, D. A. et al. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. Am. J. Gastroenterol. 103, 2562–2569 (2008).
Smith, S. C. & Wagner, M. S. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol. Lett. 35, 198–201 (2014).
Chang, L. et al. Efficacy and safety of olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: results from a phase 2b randomized study. UEG J. 9 (S8), 81 (2021).
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice. Committee on the Health Effects of Marijuana: an Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (National Academies Press, 2017).
Adejumo, A. C., Ajayi, T. O., Adegbala, O. M. & Bukong, T. N. Higher odds of irritable bowel syndrome among hospitalized patients using cannabis: a propensity-matched analysis. Eur. J. Gastroenterol. Hepatol. 31, 756–765 (2019).
Russo, E. B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol. Lett. 25, 31–39 (2004).
Patel, R. S., Goyal, H., Satodiya, R. & Tankersley, W. E. Relationship of Cannabis use disorder and irritable bowel syndrome (IBS): an analysis of 6.8 million hospitalizations in the United States. Subst. Use Misuse 55, 281–290 (2020).
Pandey, S. et al. Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy. Complement. Ther. Med. 48, 102242 (2020).
Choi, C. et al. Cannabis use is associated with reduced 30-day all-cause readmission among hospitalized patients with irritable bowel syndrome: a nationwide analysis. J. Clin. Gastroenterol. 56, 257–265 (2022).
Fichna, J. et al. Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLoS ONE 8, e85073 (2013).
Esfandyari, T. et al. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G137–G145 (2007).
Klooker, T. K., Leliefeld, K. E., Van Den Wijngaard, R. M. & Boeckxstaens, G. E. The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol. Motil. 23, 30–35 (2011).
Osborn, L. A. et al. Self-medication of somatic and psychiatric conditions using botanical marijuana. J. Psychoact. Drugs 47, 345–350 (2015).
Gonzalez, S., Cebeira, M. & Fernandez-Ruiz, J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol. Biochem. Behav. 81, 300–318 (2005).
Perisetti, A. et al. Cannabis hyperemesis syndrome: an update on the pathophysiology and management. Ann. Gastroenterol. 33, 571–578 (2020).
Higgins, P. et al. P418 Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease. J. Crohns Colitis 13, S318–S318 (2019).
Ly, H. G. et al. Increased cerebral cannabinoid-1 receptor availability is a stable feature of functional dyspepsia: a [F]MK-9470 PET study. Psychother. Psychosom. 84, 149–158 (2015).
US National Library of Medicine. ClinicalTrials.gov https://ClinicalTrials.gov/show/NCT02875678 (2017).
Weltens, N., Depoortere, I., Tack, J. & Van Oudenhove, L. Effect of acute Δ9-tetrahydrocannabinol administration on subjective and metabolic hormone responses to food stimuli and food intake in healthy humans: a randomized, placebo-controlled study. Am. J. Clin. Nutr. 109, 1051–1063 (2019).
Rock, E. M., Limebeer, C. L., Pertwee, R. G., Mechoulam, R. & Parker, L. A. Therapeutic potential of cannabidiol, cannabidiolic acid, and cannabidiolic acid methyl ester as treatments for nausea and vomiting. Cannabis Cannabinoid Res. 6, 266–274 (2021).
Sharkey, K. A., Darmani, N. A. & Parker, L. A. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur. J. Pharmacol. 722, 134–146 (2014).
Grimison, P. et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann. Oncol. 31, 1553–1560 (2020).
Jehangir, A. & Parkman, H. P. Cannabinoid use in patients with gastroparesis and related disorders: prevalence and benefit. Am. J. Gastroenterol. 114, 945–953 (2019).
McCarty, T. R., Chouairi, F., Hathorn, K. E., Chan, W. W. & Thompson, C. C. Trends and socioeconomic health outcomes of cannabis use among patients with gastroparesis: a United States nationwide inpatient sample analysis. J. Clin. Gastroenterol. 56, 324–330 (2022).
Tu, Q., Heitkemper, M. M., Jarrett, M. E. & Buchanan, D. T. Sleep disturbances in irritable bowel syndrome: a systematic review. Neurogastroenterol. Motil. 29, https://doi.org/10.1111/nmo.12946 (2017).
Simpson, N. S., Scott-Sutherland, J., Gautam, S., Sethna, N. & Haack, M. Chronic exposure to insufficient sleep alters processes of pain habituation and sensitization. Pain 159, 33–40 (2018).
Smith, M. T.Jr. et al. Sex differences in measures of central sensitization and pain sensitivity to experimental sleep disruption: implications for sex differences in chronic pain. Sleep 42, zsy209 (2019).
Babson, K. A., Sottile, J. & Morabito, D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr. Psychiatry Rep. 19, 23 (2017).
Méndez-Díaz, M., Ruiz-Contreras, A. E., Cortés-Morelos, J. & Prospéro-García, O. Cannabinoids and sleep/wake control. Adv. Exp. Med. Biol. 1297, 83–95 (2021).
Kaul, M., Zee, P. C. & Sahni, A. S. Effects of cannabinoids on sleep and their therapeutic potential for sleep disorders. Neurotherapeutics 18, 217–227 (2021).
Mondino, A. et al. Effects of cannabis consumption on sleep. Adv. Exp. Med. Biol. 1297, 147–162 (2021).
Eijsbouts, C. et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat. Genet. 53, 1543–1552 (2021).
Grigorenko, E. et al. Assessment of cannabinoid induced gene changes: tolerance and neuroprotection. Chem. Phys. Lipids 121, 257–266 (2002).
Hryhorowicz, S., Walczak, M., Zakerska-Banaszak, O., Słomski, R. & Skrzypczak-Zielińska, M. Pharmacogenetics of cannabinoids. Eur. J. Drug Metab. Pharmacokinet. 43, 1–12 (2018).
Wong, B. S. et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol. Motil. 24, 358–e169 (2012).
Bedse, G., Hill, M. N. & Patel, S. 2-Arachidonoylglycerol modulation of anxiety and stress adaptation: from grass roots to novel therapeutics. Biol. Psychiatry 88, 520–530 (2020).
O’Sullivan, S. E., Yates, A. S. & Porter, R. K. The peripheral cannabinoid receptor type 1 (CB1) as a molecular target for modulating body weight in man. Molecules 26, 6178 (2021).
Hossain, M. Z., Ando, H., Unno, S. & Kitagawa, J. Targeting peripherally restricted cannabinoid receptor 1, cannabinoid receptor 2, and endocannabinoid-degrading enzymes for the treatment of neuropathic pain including neuropathic orofacial pain. Int. J. Mol. Sci. 21, 1423 (2020).
Alger, B. E. Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know. J. Physiol. 590, 2203–2212 (2012).
Castillo, P. E., Younts, T. J., Chavez, A. E. & Hashimotodani, Y. Endocannabinoid signaling and synaptic function. Neuron 76, 70–81 (2012).
Di Marzo, V., Blumberg, P. M. & Szallasi, A. Endovanilloid signaling in pain. Curr. Opin. Neurobiol. 12, 372–379 (2002).
Gabrielsson, L., Mattsson, S. & Fowler, C. J. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br. J. Clin. Pharmacol. 82, 932–942 (2016).
Petrosino, S. & Di Marzo, V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br. J. Pharmacol. 174, 1349–1365 (2017).
Russo, R. et al. Gut-brain axis: role of lipids in the regulation of inflammation, pain and CNS diseases. Curr. Med. Chem. 25, 3930–3952 (2018).
Iannotti, F. A. & Di Marzo, V. The gut microbiome, endocannabinoids and metabolic disorders. J. Endocrinol. 248, R83–R97 (2021).
Laprairie, R. B., Bagher, A. M., Kelly, M. E. & Denovan-Wright, E. M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 172, 4790–4805 (2015).
Pacher, P., Kogan, N. M. & Mechoulam, R. Beyond THC and endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 60, 637–659 (2020).
Spanagel, R. & Bilbao, A. Approved cannabinoids for medical purposes — comparative systematic review and meta-analysis for sleep and appetite. Neuropharmacology 196, 108680 (2021).
Abuhasira, R., Shbiro, L. & Landschaft, Y. Medical use of cannabis and cannabinoids containing products — regulations in Europe and North America. Eur. J. Intern. Med. 49, 2–6 (2018).
D’Hooghe, M. et al. Sativex(R) (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. BMC Neurol. 21, 227 (2021).
Leite, C. E., Mocelin, C. A., Petersen, G. O., Leal, M. B. & Thiesen, F. V. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol. Rep. 61, 217–224 (2009).
Brodie, M. J. et al. A phase 2 randomized controlled trial of the efficacy and safety of cannabidivarin as add-on therapy in participants with inadequately controlled focal seizures. Cannabis Cannabinoid Res. 6, 528–536 (2021).
van den Elsen, G. A. H. et al. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am. J. Geriatr. Psychiatry 23, 1214–1224 (2015).
Yacyshyn, B. et al. Su1930–safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease. Gastroenterology 156, S-665 (2019).
Bloch, M. H., Landeros-Weisenberger, A., Johnson, J. A. & Leckman, J. F. A phase-2 pilot study of a therapeutic combination of Δ9-tetrahydracannabinol and palmitoylethanolamide for adults with Tourette’s syndrome. J. Neuropsychiatry Clin. Neurosci. 33, 328–336 (2021).
Light, K. & Karboune, S. Emulsion, hydrogel and emulgel systems and novel applications in cannabinoid delivery: a review. Crit. Rev. Food Sci. Nutr. https://doi.org/10.1080/10408398.2021.1926903 (2021).
Liktor-Busa, E., Keresztes, A., LaVigne, J., Streicher, J. M. & Largent-Milnes, T. M. Analgesic potential of terpenes derived from Cannabis sativa. Pharmacol. Rev. 73, 98–126 (2021).
Park, C., Zuo, J., Somayaji, V., Lee, B. J. & Lobenberg, R. Development of a novel cannabinoid-loaded microemulsion towards an improved stability and transdermal delivery. Int. J. Pharm. 604, 120766 (2021).
The authors are grateful to the National Health and Medical Research Council of Australia (Investigator Leadership Grant, APP2008727, and Development Grant APP2014250 to S.M.B.), the Australian Research Council (Discovery Project, DP180101395 to S.M.B.), Department of Veterans Affairs Senior Research Career Scientist Award (BX003610 to B.V.G.M.), Department of Veterans Affairs (Merit Grant BX002188 to B.G.V.M.), National Institutes of Health (1U01 NS113869 and 1U01NS113871 to S.M.B.; R01 NIDDK119125-01A1 to B.V.G.M.), Oklahoma Center for the Advancement of Science (HR-18-040 to B.V.G.M.), Canadian Institutes of Health Research (FDN148380 to K.A.S.), the University of Leuven (Methusalem Grant to J.T.) and the Fund for Scientific Research Flanders (Research Grants to J.T.) for support of the original research performed in the authors’ laboratories.
S.M.B. has provided scientific advice and received research grant support from AusHealth, Arena Pharmaceuticals, Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Sosie Heptares. B.V.G.M. has provided scientific advice and assistance to Nocion Therapeutics Inc., Teva Branded Pharmaceuticals Products R & D, Bayer Healthcare, Ironwood Pharmaceuticals, EA Pharma Co. Ltd and Blue Therapeutics. G.S. has provided scientific advice and assistance to Nextbiomics and has served on a Speaker bureau for AlfaSigma, Takeda, Farmagens and Interalia Pharmaceuticals. K.A.S. has provided scientific advice and assistance to Arena Pharmaceuticals and GW Pharmaceuticals and has served on a speaker bureau for Abbvie and received research support from Abalone Inc. M.S. has provided scientific advice and assistance to CaraCare, Bayer AG, Dr. Schwabe, Echo-Pharma, and Medice and has served on a Speaker bureau for Falkfoundation, Microbiotica, Bayer AG, Dr. Schwabe, Medice, Kyowa Kirin, Hexal, and HlH Biopharma. J.T. has provided scientific advice and assistance to Adare, AlfaSigma, Arena, Bayer, Christian Hansen, Clasado, Danone, Devintec, Falk, Grünenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neurogastrx, Neutec, Novartis, Nutricia, Ricordati Shionogi, Takeda, Truvion, Tsumura, Zealand, and Zeria pharmaceuticals, has served on a Speaker bureau for Abbott, Allergan, AstraZeneca, Janssen, Kiowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda, Wellspect and Zeria, and has received research support from Biohit, Kiowa Kirin, Shire, Sofar and Takeda Pharmaceuticals.
Peer review information
Nature Reviews Gastroenterology & Hepatology thanks Emeran Mayer, Ravi Bhatt, Raquel Abalo and the other anonymous reviewer for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Brierley, S.M., Greenwood-Van Meerveld, B., Sarnelli, G. et al. Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome. Nat Rev Gastroenterol Hepatol (2022). https://doi.org/10.1038/s41575-022-00682-y